top of page
CathHELIX Catheter System

The CathHELIX   Solution

Building on the principles of annuloplasty, smart engineering and design combine to create an advanced mitral regurgitation treatment option providing:

Ease of implant placement and retention

Reliable implant securement

Efficient procedure time with concise learning curve

Standard echo views supported by TEE

Confidence in the result and in knowing future treatment options remain 

BKD_2
Annuloplasty

CathHELIX provides the benefits of an annuloplasty – a proven, lasting treatment for mitral valve repair – while using a familiar transcatheter approach.

​​

After reducing the annulus with the Mitral Annulus Reduction System (MARS), the unique self-securing CathHELIX ring is deployed, automatically securing itself in the atrial supra-annular groove and on the ventricular side in the sub-annular groove of the reduced annulus. 

1

  1. Baldus S, Doenst T, Pfister R, et al. Transcatheter repair versus mitral-valve surgery for secondary mitral regurgitation. N Engl J Med. DOI: 10.1056/NEJMoa2408739. nejmoa2408739_appendix.pdf

The FDA granted CathHELIX™ a
Breakthrough Device Designation
and has continued to closely collaborate with HVR Cardio
Microscope icon
HVR Cardio logo

HVR Cardio Oy

Upseerinkatu 1, Tower 1

02600 Espoo, Finland

HVR Cardio US Inc.

14530 Martin Drive

Suite 100

Eden Prairie, MN 55344

LinkedIn logo

CAUTION: Investigational device. Limited by Federal (United States) law to investigational use only. CathHELIX™ is not commercially available and is intended for investigational use only. Performance specifications and claims are subject to revision pending completion of regulatory approvals. CathHELIX™ is a trademark of HVR Cardio Oy.

 

© 2025 HVR Cardio Oy. All rights reserved.

bottom of page